Evidence map›Paper›PMID 33656690›Full record

ArticleJournal of gastrointestinal cancer2022

The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study.

Serdar NazimTurhal, Mutlu Dogan, Guldal Esendagli, Mehmet Artac, Levent Korkmaz, Hasan Senol Coskun, Erdem Goker, Fulden PerranYumuk, Irem Bilgetekin, Fatih Kose and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Serdar NazimTurhalDepartment of Medical Oncology, Anadolu Medical Center, Istanbul, Turkey.
Mutlu DoganDepartment of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey. mutludogan1@yahoo.com.ORCID http://orcid.org/0000-0001-9359-3770
Guldal EsendagliDepartment of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Mehmet ArtacDepartment of Medical Oncology, Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey.
Levent KorkmazDepartment of Computer Engineering, Faculty of Engineering, Istinye University, Istanbul, Turkey.
Hasan Senol CoskunDepartment of Medical Oncology, Akdeniz UniversityFaculty of Medicine, Antalya, Turkey.
Erdem GokerDepartment of Medical Oncology, Ege UniversityFaculty of Medicine, Izmir, Turkey.
Fulden PerranYumukDepartment of Medical Oncology, Marmara UniversityFaculty of Medicine, Istanbul, Turkey.
Irem BilgetekinDepartment of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey.
Fatih KoseDepartment of Medical Oncology, Faculty of Medicine, Baskent University, Adana, Turkey.
Dogan UncuDepartment of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Halil KavgaciDepartment of Medical Oncology, Faculty of Medicine, Karadeniz University, Trabzon, Turkey.
Gulen AkyolDepartment of Pathology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Ahmet OzetDepartment of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Tamer YagciDepartment of Molecular Biology and Genetics, Faculty of Basic Sciences, Gebze Technical University, Kocaeli, Turkey.
Gazi University · TRAkdeniz University · TRAnadolu University · TRAnkara Numune Eğitim ve Araştırma Hastanesi · TRBaşkent University · TREge University · TRGebze Technical University · TRIstinye University · TRKaradeniz Technical University · TRMarmara University · TRMinistry of Health · TRNecmettin Erbakan University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePlexin C1 is a transmembrane receptor and plexin C1 overexpression might have role in carcinogenesis. Hepatocellular carcinoma (HCC) has poor prognosis because of its aggressive behavior and limited treatment options, especially in advanced stage. We recently documented that Plexin C1 was overexpressed in HCC. We aimed to evaluate the prognostic significance of Plexin C1 overexpression in HCC in the present study.

methodsPlexin C1 overexpression was evaluated immunohistochemically on paraffin-embedded blocks of the HCC patients. Plexin C1 immunohistochemical staining was scored. Plexin C1 overexpression staining intensity and prevalence were used for plexin scale staining evaluation and plexin scores were estimated according this staining scale. Plexin C1 score and its association with survival and clinicopathological features was assessed.

resultsSixty-seven HCC patients with adequate tissue for pathological evaluation were included. Median age was 63 years with male predominance (male to female ratio was 4.75 (n 57/12). Well-differentiated HCC (53.7%) patients had higher plexin C1 overexpression (p < 0.05). Median OS was 22.1 months. Patients with lower plexin C1 score (< 12) had shorter OS (17.5 vs 30.1 months, p = 0.036). Neutrophil count, GGT, and PNR (platelet/neutrophil ratio) had prognostic significance (p = 0.047, p = 0.018, and p = 0.045).

conclusionPlexin C1 overexpression is inversely correlated with grade in HCC. The patients with lower rate of Plexin C1 overexpression have worse survival outcome. It might be a prognostic factor in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsReceptors, VirusBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisTurkeyBiomarkers, TumorReceptors, VirusVESPR semaphorin receptorHccHepatocellular carcinomaPlexin

Identifiers

PMID33656690
OpenAlexW3133881314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.